Collaboration between Delphi Genetics and Avaxia biologics (MA, USA)
Delphi Genetics will collaborate with Avaxia Biologics (Lexington, Massachusetts) for the development of efficient antibodies against TNF. "It is a very exciting project that perfectly synergizes with the existing developments of Delphi Genetics. Moreover, it will strengthen our activities using our Staby® technology for the production of DNA and proteins at high yield and without antibiotic resistance genes. The collaboration with Avaxia is a very good opportunity for us to translate our technological expertise into concrete projects with future commercialization potential. Of course, we hope that this project will be the starting point of a long-term collaboration with Avaxia" says Cédric Szpirer, CEO/CSO.
For more information, see the press release or the Health blog of Wallonia.